Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03468309 · ClinicalTrials.gov registry record
Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population
A clinical trial of Pharmacogenetic Testing, sponsored by Seattle Institute for Biomedical and Clinical Research.
- Completed
- Registry status
- 53
- Enrollment target
- 1
- Study location
NCT03468309: Completed study of Pharmacogenetic Testing, sponsored by Seattle Institute for Biomedical and Clinical Research.
NCT03468309 is a study of Pharmacogenetic Testing that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 53 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03468309, a study of Pharmacogenetic Testing, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.
- COMPLETED
- Registry status
- 53 participants
- Enrollment target
- 1
- Study location
Study Summary
Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects. Pharmacogenetic assays, such as the Genecept® Assay, have the purported benefit of being able to predict response(s) to specific medication based on genetic markers. Thus, this study is a 12-week open-label, naturalistic study of the provision of pharmacogenetic testing and a computerized decision tool for providers to determine the potential efficacy of the assay to reduce polypharmacy and improve patient outcomes.
Primary Outcome
Clinical Global Impression. Range is 1-6, with 1 = less symptomology and 6 = high symptomology.
Conditions Studied
Interventions
- GENETIC Genecept Assay and G-DIG decision tool
Study Locations (1)
Washington
- VA Puget Sound Health Care System - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2018-01-01 |
| Est. Completion | 2024-04-17 |
What the finished NCT03468309 record still lists
NCT03468309 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 53 participants, a relatively small participant target.
The record links to 1 condition, with Pharmacogenetic Testing appearing as the primary indexed condition, and to 1 intervention - of which Genecept Assay and G-DIG decision tool is the first listed.
NCT03468309 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03468309 about?
NCT03468309 is a clinical study titled "Medication Optimization Using Pharmacogenetic Testing and the G-DIG to Reduce Polypharmacy in a Mental Health Population". Use of polypharmacy has significantly increased over the past two decades, which has unproven clinical benefit and is associate with an increased the risk of adverse side effects. Pharmacogenetic assays, such as the Genecept® Assay, have the purported benefit of being able to predict response(s) to ...
What is the current status of trial NCT03468309?
This trial is currently completed. The enrollment target is 53 participants. The study started on 2018-01-01. Estimated completion is 2024-04-17.
What conditions does trial NCT03468309 study?
This clinical trial studies the following conditions: Pharmacogenetic Testing.
What interventions are being tested in trial NCT03468309?
The interventions under investigation include: Genecept Assay and G-DIG decision tool (GENETIC).
Who is sponsoring clinical trial NCT03468309?
This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03468309 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pharmacogenetic Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04177004 · 53 participants · Phase 1
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant
- NCT04199741 · 53 participants · Phase 1
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56
- NCT04835129 · 53 participants · Phase 2
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
- NCT04913805 · 53 participants · Phase 2
Matching Perfusion and Metabolic Activity in HFpEF
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI